UBS AM
PVLA

UBS AM’s Palvella Therapeutics PVLA Stock Holding History

UBS AM’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Sell
67,469
-2,432
-3% -$295K ﹤0.01% 1229
2026
Q1 		$8.71M Buy
69,901
+22,220
+47% +$2.32M ﹤0.01% 1258
2025
Q4 		$4.99M Buy
+47,681
New +$4.07M ﹤0.01% 1465

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

UBS AM's PVLA Position: Q2 2026 in Review

UBS AM reduced its Palvella Therapeutics (PVLA) stake by 3.5% in Q2 2026, selling an estimated $295K and leaving 67,469 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1229.

UBS AM first reported a position in PVLA in Q4 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • UBS AM held 67,469 shares of Palvella Therapeutics worth $10.3M as of Q2 2026.
  • UBS AM sold 2,432 Palvella Therapeutics shares in Q2 2026, an estimated $295K.
  • Palvella Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1229 holding.
  • UBS AM first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.